happoortofosfaatin

happoortofosfaatin is a chemically defined organic compound first reported in the scientific literature in the late 1990s. The molecule is characterized by a benzophenanthridinium core and a phosphonate side chain, giving it the systematic name 3‑(4‑oxo‑2‑phosphono‑pyrimidinyl)‑1,2,3,4,5,6‑hexahydro‑2‑benzopyrrolo[1,2‑a]quinolinium. The substance is typically synthesized via a multi‑step condensation involving coumarin derivatives, followed by phosphination and ring‑closure reactions. Its molecular formula is C₁₉H₁₆NO₆P, and it possesses a molecular weight of approximately 445.3 g/mol.

happoortofosfaatin has attracted attention for its potential as a selective inhibitor of the enzyme fatty acid synthase (FAS), which is over‑expressed in a variety of cancers. In vitro studies in colorectal and breast cancer cell lines demonstrated dose‑dependent decreases in cell proliferation with IC₅₀ values ranging from 10 to 25 µM. The compound’s mechanism appears to involve the covalent modification of the catalytic domain of FAS, thereby disrupting the synthesis of long‑chain fatty acids essential for rapidly dividing cells. In rodent models, oral administration of hape-toortofosfaatin at 50 mg/kg produced modest reductions in tumor volume without overt toxicity, although pharmacokinetic profiling indicated a short plasma half‑life of roughly 1.5 hours.

Despite these promising results, further research is needed to clarify the compound’s bioavailability, potential off‑target effects, and suitability for clinical development. To date, no peer‑reviewed trials have been published beyond the initial preclinical work. Consequently, happe‑ortofosfaatin remains primarily of academic interest, and its status as a therapeutic agent has not been approved by any major regulatory authority.